Tumor microenvironment drives first-in-human innovation at ESMO 2025

Beyond the late-stage ADCs that dominated the headlines, this year’s ESMO Congress also showcased new ways to modulate the tumor microenvironment, the latest PD-1 x VEGF bispecific designs, and a spate of novel targets.

To uncover translational research themes at the 2025 European Society of Clinical Oncology (ESMO) meeting, BioCentury analyzed abstracts offering a first glimpse of efficacy, with data from first-in-human trials and abstracts on studies in progress. ...